• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $REPL

    Replimune Group Inc.

    Subscribe to $REPL
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

    IPO Year: 2018

    Exchange: NASDAQ

    Website: replimune.com

    Recent Analyst Ratings for Replimune Group Inc.

    DatePrice TargetRatingAnalyst
    7/30/2025Neutral → Overweight
    Cantor Fitzgerald
    7/23/2025$2.00Outperform → Underperform
    BMO Capital Markets
    7/23/2025Buy → Neutral
    H.C. Wainwright
    7/23/2025$3.00Overweight → Equal Weight
    Barclays
    7/22/2025$3.00Outperform → Market Perform
    Leerink Partners
    7/22/2025$9.00Overweight → Neutral
    Analyst
    7/22/2025$4.00Outperform → Neutral
    Wedbush
    7/22/2025$3.00Overweight → Neutral
    Piper Sandler
    6/20/2025Overweight
    Cantor Fitzgerald
    8/28/2024$17.00Buy
    ROTH MKM
    See more ratings

    Replimune Group Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Astley-Sparke Philip sold $260,169 worth of shares (32,279 units at $8.06), decreasing direct ownership by 2% to 1,405,071 units (SEC Form 4)

    4 - Replimune Group, Inc. (0001737953) (Issuer)

    5/22/25 9:47:07 PM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Medical Officer Xynos Konstantinos sold $64,093 worth of shares (7,952 units at $8.06), decreasing direct ownership by 5% to 146,933 units (SEC Form 4)

    4 - Replimune Group, Inc. (0001737953) (Issuer)

    5/22/25 9:46:09 PM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Accounting Officer Schwendenman Andrew sold $26,460 worth of shares (3,287 units at $8.05), decreasing direct ownership by 5% to 68,284 units (SEC Form 4)

    4 - Replimune Group, Inc. (0001737953) (Issuer)

    5/22/25 9:45:30 PM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Executive Officer Patel Sushil sold $202,346 worth of shares (25,105 units at $8.06), decreasing direct ownership by 7% to 343,576 units (SEC Form 4)

    4 - Replimune Group, Inc. (0001737953) (Issuer)

    5/22/25 9:44:48 PM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Financial Officer Hill Emily Luisa sold $20,407 worth of shares (2,535 units at $8.05), decreasing direct ownership by 2% to 143,522 units (SEC Form 4)

    4 - Replimune Group, Inc. (0001737953) (Issuer)

    5/22/25 9:44:01 PM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Commercial Officer Sarchi Christopher sold $30,179 worth of shares (3,749 units at $8.05), decreasing direct ownership by 3% to 128,296 units (SEC Form 4)

    4 - Replimune Group, Inc. (0001737953) (Issuer)

    5/22/25 9:42:32 PM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Peeples-Dyer Veleka

    4 - Replimune Group, Inc. (0001737953) (Issuer)

    4/3/25 8:06:46 PM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Executive Officer Patel Sushil was granted 166,667 shares, increasing direct ownership by 83% to 368,681 units (SEC Form 4)

    4 - Replimune Group, Inc. (0001737953) (Issuer)

    4/3/25 8:06:13 PM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Pucci Paolo

    4 - Replimune Group, Inc. (0001737953) (Issuer)

    4/3/25 8:05:36 PM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Balachandran Madhavan

    4 - Replimune Group, Inc. (0001737953) (Issuer)

    4/3/25 8:05:09 PM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Replimune Group Inc. Press Releases

    Fastest customizable press release news feed in the world

    View All

    Replimune Reports Fiscal First Quarter 2026 Financial Results and Provides Corporate Update

    WOBURN, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal first quarter ended June 30, 2025 and provided a business update. The Company announced on July 22, 2025 that the U.S. Food and Drug Administration (FDA) had issued a Complete Response Letter (CRL) for the RP1 BLA in advanced melanoma. "Based on the compelling clinical data and safety profile generated to date with RP1 in the IGNYTE study, the melanoma community, including clinical experts and patients, strongly believe RP1 should be made available to pat

    8/7/25 8:00:00 AM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Replimune Receives Complete Response Letter from FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma

    WOBURN, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the Biologics License Application (BLA) for RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of advanced melanoma. The CRL indicates that the FDA is unable to approve the application in its present form. The FDA has indicated that the IGNYTE trial is not considered to be an adequate and well-controlled clinical investigation that provides substantial eviden

    7/22/25 7:00:00 AM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    WOBURN, Mass., July 11, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of inducement equity awards to newly hired non-executive employees. The Company granted equity awards to 16 employees as a material inducement to commencing their employment with the Company under the Company's 2025 Inducement Grant Incentive Compensation Plan (the "Inducement Plan"). The inducement awards consist of non-qualified stock options to purchase an aggregate of 32,135 shares of the Company's common stock and restricted stock units representing an aggregate of 64,320 s

    7/11/25 4:01:00 PM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    WOBURN, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of inducement equity awards to newly hired non-executive employees. The Company granted equity awards to 10 employees as a material inducement to commencing their employment with the Company under the Company's 2025 Inducement Grant Incentive Compensation Plan (the "Inducement Plan"). The inducement awards consist of non-qualified stock options to purchase an aggregate of 36,485 shares of the Company's common stock and restricted stock units representing an aggregate of 41,080 s

    6/6/25 4:01:00 PM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

    - RP1 plus nivolumab generated robust responses in both injected and non-injected lesions - - Deep/visceral injections, including into the liver and lung, resulted in numerically higher rates of response compared to superficial injections only and were generally well tolerated - WOBURN, Mass., June 01, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today presented two posters highlighting data updates for RP1 (vusolimogene oderparepvec) at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 30-June 3 in Chicago. "The new analyses we pres

    6/1/25 10:00:00 AM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Replimune to Present at the 2025 Jefferies Global Healthcare Conference

    WOBURN, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that members of the Replimune management team will present in a fireside chat at the 2025 Jefferies Global Healthcare Conference on Thursday, June 5, 2025 at 4:20 PM ET. A simultaneous webcast will be available in the Investors section of Replimune's website at replimune.com. A replay will be available for 30 days following the conference. About Replimune Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering th

    5/29/25 8:00:00 AM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Replimune Reports Fiscal Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update

    •  BLA priority review of RP1 plus nivolumab in advanced melanoma proceeding on schedule; manufacturing inspections and late cycle review meeting complete •  Full commercial infrastructure for launch in place ahead of July 22nd PDUFA date •  Conference call today at 8:00 AM ET WOBURN, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal fourth quarter and year ended March 31, 2025 and provided a business update. "As we near our PDUFA date, our commercial organization is now fully hired and ready to execute our fir

    5/22/25 7:00:00 AM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Replimune Announces Dates for Fiscal Fourth Quarter and Year End 2025 Financial Results and Upcoming Investor Day

    WOBURN, Mass., May 16, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that it will host a conference call on Thursday, May 22, 2025 at 8:00 a.m. ET to discuss its financial results for the fiscal fourth quarter and year end March 31, 2025. Additionally, the Company will host an Investor Day on Tuesday, June 24, 2025. Fiscal Fourth Quarter Earnings Replimune will release its fiscal year end earnings and host a conference call at 8:00 a.m. ET on May 22, 2025. Listeners can register for the webcast via this link. Analysts wishing to participate in the

    5/16/25 8:00:00 AM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    WOBURN, Mass., May 09, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of inducement equity awards to newly hired non-executive employees. The Company granted equity awards to 18 employees as a material inducement to commencing their employment with the Company under the Company's 2025 Inducement Grant Incentive Compensation Plan (the "Inducement Plan"). The inducement awards consist of non-qualified stock options to purchase an aggregate of 21,960 shares of the Company's common stock and restricted stock units representing an aggregate of 44,005 sh

    5/9/25 4:01:00 PM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Sibylla Biotech Appoints Former Bayer CEO, Dieter Weinand, as Chairman of the Board of Directors

    Milan, Italy, May 8, 2025 – Sibylla Biotech today announced the appointment of Dieter Weinand as Chairman of its Board of Directors. Mr. Weinand is an industry veteran, boasting over 35 years in the pharmaceutical sector, including leading business units and drug commercialization initiatives at global organizations. His background includes serving as President, CEO and Chairman of the Board of Bayer Pharmaceuticals AG. At Sibylla, Mr. Weinand's profound knowledge will guide the Board as the company advances its innovative Pharmacological Protein Inactivation by Folding Intermediates Targeting (PPI-FIT) technology and pipeline of folding interference small molecules to address a range of cha

    5/8/25 5:00:00 AM ET
    $COYA
    $REPL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Replimune Group Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Replimune upgraded by Cantor Fitzgerald

    Cantor Fitzgerald upgraded Replimune from Neutral to Overweight

    7/30/25 1:46:11 PM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Replimune downgraded by BMO Capital Markets with a new price target

    BMO Capital Markets downgraded Replimune from Outperform to Underperform and set a new price target of $2.00

    7/23/25 7:43:21 AM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Replimune downgraded by H.C. Wainwright

    H.C. Wainwright downgraded Replimune from Buy to Neutral

    7/23/25 7:42:18 AM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Replimune downgraded by Barclays with a new price target

    Barclays downgraded Replimune from Overweight to Equal Weight and set a new price target of $3.00

    7/23/25 7:42:18 AM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Replimune downgraded by Leerink Partners with a new price target

    Leerink Partners downgraded Replimune from Outperform to Market Perform and set a new price target of $3.00

    7/22/25 12:36:27 PM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Replimune downgraded by Analyst with a new price target

    Analyst downgraded Replimune from Overweight to Neutral and set a new price target of $9.00

    7/22/25 10:43:48 AM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Replimune downgraded by Wedbush with a new price target

    Wedbush downgraded Replimune from Outperform to Neutral and set a new price target of $4.00

    7/22/25 9:57:14 AM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Replimune downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded Replimune from Overweight to Neutral and set a new price target of $3.00

    7/22/25 9:57:14 AM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cantor Fitzgerald initiated coverage on Replimune

    Cantor Fitzgerald initiated coverage of Replimune with a rating of Overweight

    6/20/25 7:54:39 AM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    ROTH MKM initiated coverage on Replimune with a new price target

    ROTH MKM initiated coverage of Replimune with a rating of Buy and set a new price target of $17.00

    8/28/24 7:52:10 AM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Replimune Group Inc. SEC Filings

    View All

    SEC Form 10-Q filed by Replimune Group Inc.

    10-Q - Replimune Group, Inc. (0001737953) (Filer)

    8/7/25 8:07:39 AM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Replimune Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Replimune Group, Inc. (0001737953) (Filer)

    8/7/25 8:05:39 AM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SCHEDULE 13G filed by Replimune Group Inc.

    SCHEDULE 13G - Replimune Group, Inc. (0001737953) (Subject)

    7/31/25 4:05:16 PM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form DEFA14A filed by Replimune Group Inc.

    DEFA14A - Replimune Group, Inc. (0001737953) (Filer)

    7/25/25 4:18:29 PM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form DEF 14A filed by Replimune Group Inc.

    DEF 14A - Replimune Group, Inc. (0001737953) (Filer)

    7/25/25 4:16:04 PM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Replimune Group Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Replimune Group, Inc. (0001737953) (Filer)

    7/22/25 8:18:47 AM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Replimune Group Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Replimune Group, Inc. (0001737953) (Filer)

    6/24/25 4:30:37 PM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form S-3 filed by Replimune Group Inc.

    S-3 - Replimune Group, Inc. (0001737953) (Filer)

    5/22/25 9:34:00 PM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form S-3 filed by Replimune Group Inc.

    S-3 - Replimune Group, Inc. (0001737953) (Filer)

    5/22/25 9:30:37 PM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form S-8 filed by Replimune Group Inc.

    S-8 - Replimune Group, Inc. (0001737953) (Filer)

    5/22/25 9:23:59 PM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Replimune Group Inc. Financials

    Live finance-specific insights

    View All

    Replimune Announces Dates for Fiscal Fourth Quarter and Year End 2025 Financial Results and Upcoming Investor Day

    WOBURN, Mass., May 16, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that it will host a conference call on Thursday, May 22, 2025 at 8:00 a.m. ET to discuss its financial results for the fiscal fourth quarter and year end March 31, 2025. Additionally, the Company will host an Investor Day on Tuesday, June 24, 2025. Fiscal Fourth Quarter Earnings Replimune will release its fiscal year end earnings and host a conference call at 8:00 a.m. ET on May 22, 2025. Listeners can register for the webcast via this link. Analysts wishing to participate in the

    5/16/25 8:00:00 AM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Replimune Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma

    Primary endpoint data shows 12-month overall response rate (ORR) of 33.6% Biologics license application (BLA) submission intended for 2H 2024; first patient expected to be enrolled in IGNYTE-3 confirmatory trial in Q3 2024 Company to host conference call and webcast today at 8:00 a.m. ET WOBURN, Mass., June 06, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced the topline results from the primary analysis of the IGNYTE clinical trial of RP1 plus nivolumab in anti-PD1 failed melanoma. The results by independent central review show one-third of pat

    6/6/24 7:00:00 AM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Replimune Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failed Melanoma and Non-Melanoma Skin Cancers

    RP1 in combination with cemiplimab demonstrated clinically meaningful improvements in complete response rate and duration of response compared to cemiplimab in the CERPASS clinical trial, but did not meet either of the two primary endpoints Positive data update for full 140 patients in the IGNYTE clinical trial cohort of RP1 in anti-PD1 failed melanoma reinforces durable benefit; biologics license application (BLA) submission planned for 2H 2024 RP1 monotherapy data from ARTACUS clinical trial and new data from first 30 patients with anti-PD1 failed non-melanoma skin cancers in IGNYTE trial adds to growing body of evidence supporting the potential of RP1 in difficult to treat skin cancer s

    12/5/23 7:00:00 AM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Replimune Reports Fiscal Second Quarter 2024 Financial Results and Provides Corporate Update

    The Company plans to hold a conference call in early December to provide a comprehensive RP1 skin cancer program update including: Topline data from the CERPASS clinical trial of RP1 combined with Libtayo in cutaneous squamous cell carcinomaAn initial data snapshot for all 140 patients in the IGNYTE clinical trial cohort of RP1 in anti-PD1 failed melanomaInitial data from the IGNYTE cohort of RP1 in anti-PD1 failed non-melanoma skin cancersA recap of interim data from the ARTACUS clinical trial of RP1 monotherapy in solid organ transplant recipients with skin cancer recently presented at SITC 2023 WOBURN, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:

    11/7/23 8:00:00 AM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Replimune Group Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Replimune Group Inc.

    SC 13G/A - Replimune Group, Inc. (0001737953) (Subject)

    11/14/24 4:20:10 PM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Replimune Group Inc.

    SC 13G/A - Replimune Group, Inc. (0001737953) (Subject)

    11/14/24 1:22:38 PM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Replimune Group Inc.

    SC 13G/A - Replimune Group, Inc. (0001737953) (Subject)

    11/14/24 8:35:56 AM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Replimune Group Inc.

    SC 13G/A - Replimune Group, Inc. (0001737953) (Subject)

    11/14/24 7:00:55 AM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Replimune Group Inc.

    SC 13G/A - Replimune Group, Inc. (0001737953) (Subject)

    11/12/24 4:51:28 PM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Replimune Group Inc.

    SC 13G/A - Replimune Group, Inc. (0001737953) (Subject)

    11/4/24 1:53:18 PM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Replimune Group Inc.

    SC 13G/A - Replimune Group, Inc. (0001737953) (Subject)

    10/7/24 4:38:31 PM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Replimune Group Inc.

    SC 13G/A - Replimune Group, Inc. (0001737953) (Subject)

    7/10/24 6:44:39 AM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Replimune Group Inc. (Amendment)

    SC 13G/A - Replimune Group, Inc. (0001737953) (Subject)

    4/10/24 12:58:49 PM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Replimune Group Inc. (Amendment)

    SC 13G/A - Replimune Group, Inc. (0001737953) (Subject)

    4/10/24 9:48:48 AM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Replimune Group Inc. Leadership Updates

    Live Leadership Updates

    View All

    Sibylla Biotech Appoints Former Bayer CEO, Dieter Weinand, as Chairman of the Board of Directors

    Milan, Italy, May 8, 2025 – Sibylla Biotech today announced the appointment of Dieter Weinand as Chairman of its Board of Directors. Mr. Weinand is an industry veteran, boasting over 35 years in the pharmaceutical sector, including leading business units and drug commercialization initiatives at global organizations. His background includes serving as President, CEO and Chairman of the Board of Bayer Pharmaceuticals AG. At Sibylla, Mr. Weinand's profound knowledge will guide the Board as the company advances its innovative Pharmacological Protein Inactivation by Folding Intermediates Targeting (PPI-FIT) technology and pipeline of folding interference small molecules to address a range of cha

    5/8/25 5:00:00 AM ET
    $COYA
    $REPL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Replimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitions

    Philip Astley-Sparke to transition from current role of CEO to Executive Chairman Planned leadership changes position the Company for commercialization Preparations on track to submit RP1 biologics license application (BLA) in 2H 2024 WOBURN, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced changes to its executive leadership team designed to support the Company's preparations for the commercial launch of RP1, pending regulatory submission and approval in anti-PD1 failed melanoma. Sushil Patel, Ph.D., will succeed Philip

    3/26/24 7:30:00 AM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tessellate BIO Emerges from Stealth

    The company aims to become a global leader in precision oncology by redefining Synthetic Lethality to treat large, currently unserved patient populationsLead program targets Alternative Lengthening of Telomeres (ALT) through the FANCM protein complexCompany backed by leading venture firms, BioGeneration Ventures (BGV) and ForbionWorld-class leadership team with proven experience as entrepreneurs and deep expertise in drug discovery and precision oncology AMSTERDAM and LONDON, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Tessellate BIO, a preclinical stage biotechnology company with a focus on novel Synthetic Lethality approaches, has today emerged from stealth, with an initial €8m in s

    10/17/23 3:00:00 AM ET
    $NAMS
    $REPL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Replimune Announces Appointment of Emily Hill as Chief Financial Officer

    WOBURN, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, today announced the appointment of Emily Hill as Chief Financial Officer. Ms. Hill was most recently CFO of the commercial stage biotech company PTC Therapeutics and has more than 15 years of experience in the biotechnology and life sciences industry having held senior financial management and investor relations roles at several leading public biotechnology and pharmaceutical companies. "Emily brings a wealth of financial planning and strategy experience to Replimune that will be impactfu

    9/19/23 8:00:00 AM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Former CEO and Chairman of the Board of Bayer Pharma AG, Dieter Weinand, Joins Coya's Board of Directors

    Mr. Weinand is the former CEO and Chairman of the Board at Bayer Pharma AG, leading Bayer's fully integrated $20 billion healthcare business Mr. Weinand is a seasoned business leader with over 25 years of experience leading business and strategic operations for companies including Bayer, Pfizer, Bristol Myers Squibb, Sanofi, and Otsuka Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance the function of Regulatory T Cells (Tregs), today announced that it has appointed Mr. Dieter Weinand to its board of directors, effective immediately. Coya will leverage Mr. Weinand's extens

    8/21/23 7:00:00 AM ET
    $COYA
    $REPL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Replimune Reports Fiscal First Quarter 2024 Financial Results and Provides Corporate Update

    Topline data from the registration-directed CERPASS clinical trial of RP1 combined with Libtayo® (cemiplimab-rwlc) in cutaneous squamous cell carcinoma expected in early Q4 2023 and Biologics License Application submission anticipated in Q1/2 2024 Cost sharing collaboration in cutaneous squamous cell carcinoma in the neoadjuvant setting entered into with Incyte Data snapshot for all 141 patients in the IGNYTE clinical trial cohort of RP1 in anti-PD1 failed melanoma expected Q4 2023 RP2 and RP3 Phase 2 programs; third-line colorectal cancer clinical trial initiated, first- and second-line hepatocellular carcinoma trials expected to initiate this quarter; Phase 1 clinical trial

    8/3/23 8:00:00 AM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Replimune Appoints Veleka R. Peeples-Dyer to its Board of Directors

    WOBURN, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, today announced the appointment of Veleka R. Peeples-Dyer to the Company's Board of Directors effective June 1, 2023. "We are pleased to welcome Veleka to Replimune's Board of Directors," said Philip Astley-Sparke, Chief Executive Officer of Replimune. "Veleka is a highly accomplished life sciences executive, experienced attorney and compliance professional with over 24 years of her practice dedicated to the life sciences industry assisting with building legal and compliance

    6/5/23 8:00:00 AM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Forbion appoints Silva Deželan, PhD as Head of Impact and ESG

    NAARDEN, Netherlands and MUNICH, Germany, May 04, 2023 (GLOBE NEWSWIRE) -- Forbion, a leading European life sciences venture capital firm, announces the appointment of Silva Deželan PhD, as Forbion's first Head of Impact & ESG. Silva has over 15 years of experience in ESG integration, sustainability and impact investing, including private equity, most recently as ESG Director at Stafford Capital Partners and before that as Director, Sustainability, Private Equity at Robeco. Silva contributes her knowledge of ESG best-practice to a number of professional organizations, including as vice-chair of Invest Europe's ESG Committee, and as a member of the Responsible Investment Committee of the Du

    5/4/23 8:59:15 AM ET
    $NAMS
    $REPL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Replimune Appoints Former Sanofi U.S. Commercial Oncology Head, Chris Sarchi, as Chief Commercial Officer and Sushil Patel as Chief Strategy Officer

    WOBURN, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies (TDOIs), announced today the appointment of Christopher Sarchi as Replimune's Chief Commercial Officer and the appointment of Sushil Patel, Ph.D., previously Replimune's Chief Commercial Officer, to a newly created position of Chief Strategy Officer, effective immediately. "These leadership appointments provide broad strategic and operational commercial acumen as we ramp up our commercial planning ahead of the potential 2024 commercial launch of RP1," said Philip Astley-Sparke, C

    1/4/23 8:00:00 AM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Replimune Appoints Christy Oliger to its Board of Directors

    WOBURN, Mass., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a biotechnology company developing a range of product candidates derived from its oncolytic immuno-gene therapy platform, today announced the appointment of Christy Oliger to the Company's Board of Directors effective December 1, 2021. "We are delighted to welcome Christy to Replimune's Board of Directors," said Philip Astley-Sparke, Chief Executive Officer of Replimune. "Christy brings nearly 30 years of commercial and business experience in the pharmaceutical and biotechnology industry foremostly in oncology. We look forward to working with Christy and believe her guidance and input will strengthen our

    12/2/21 8:00:00 AM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care